Patricia V. Aguilar*, Ivorlyne P. Greene*, Lark L. Coffey*, Gladys Medina*
1, Abelardo C. Moncayo*
2, Michael Anishchenko*, George V. Ludwig†, Michael J. Turell‡, Monica L. O’Guinn‡, John Lee‡, Robert B. Tesh*, Douglas M. Watts†, Kevin L. Russell†, Christine Hice*, Stephen Yanoviak*, Amy C. Morrison§, Terry A. Klein‡, David J. Dohm‡, Hilda Guzman*, Amelia P.A. Travassos da Rosa*, Carolina Guevara†, Tadeusz Kochel†, James Olson†, Cesar Cabezas¶, and Scott C. Weaver*
Author affiliations: *University of Texas Medical Branch, Galveston, Texas, USA; †Naval Medical Research Center Detachment, Lima, Peru; ‡U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; §University of California, Davis, California, USA; ¶Instituto Nacional de Salud, Lima, Peru
Main Article
Table 4
Results of the plaque reduction neutralization tests between members of Venezuelan equine encephalitis subtype IIIa
|
Antiserum (subtype/variety) |
Virus strain (subtype/variety)
|
Mucambo (IIIA)
|
Tonate (IIIB)
|
71D1252 (IIIC)
|
PE407660 (IIID)
|
Mucambo (IIIA)
|
1
|
2
|
16
|
8
|
Tonate (IIIB)
|
4
|
1
|
>160
|
8
|
71D1252 (IIIC)
|
>32
|
4
|
1
|
2
|
| PE4.07660 (IIID) |
8 |
16 |
2 |
1 |
Main Article
Top of Page